Community-Acquired Pneumonia (CAP)
pulmonary venous hypertension :: Article Creator Insmed Stock Soars On Pulmonary Arterial Hypertension Drug Trial Results Shares of Insmed (INSM) jumped nearly 30% Tuesday after the biopharmaceutical company reported positive results from a Phase 2 trial for its treatment of pulmonary arterial hypertension. The Bridgewater, N.J.-based company said the study was "evaluating the efficacy and safety of treprostinil palmitil inhalation powder" in patients with pulmonary arterial hypertension, or PAH, and that the trial "met its primary endpoint and all secondary efficacy endpoints." Pulmonary hypertension, which develops when the blood pressure in your lungs is higher than normal, affects about 1% of people globally, per the National Heart, Lung, and Blood Institute. Insmed said it would "immediately engage with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 trial design for PAH. Insmed plans to in...
